Umifenovir (Arbidol) Efficacy in Experimental Mixed Viral and Bacterial Pneumonia of Mice
Abstract
Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S.aureus pneumonia following A/California/04/2009 (H1N1) influenza virus infection . Oral treatment with umifenovir (40 and 60 mg/kg/day ) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by >2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
About the Authors
I. A. Leneva
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
I. N. Falynskova
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
E. I. Leonova
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
I. T. Fedyakina
Ivanovsky Institute of Virology, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. R. Makhmudova
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
E. A. Osipova
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
L. N. Lepekha
Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
N. A. Mikhailova
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
V. V. Zverev
I. I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Science
Russian Federation
Russian Federation
References
1. Legand A., Briand S., Shindo N., Brooks W.A., de Jong M., Farrar J., Aguilera J., Hayden F. G. Addressing the public health burden of respiratory viruses the battle against respiratory viruses (BRaVe). Initiative Future Virology. 2013; 8: 10: 953-968.
2. Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann N Y Acad Sci 2014; 1323: 1: 115-139.
3. Center for Disease Control and Prevention. Antiviral agents for influenza guidance on the use of influenza antiviral agents. Available at: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed 5 March 2014.
4. Boriskin Y., Leneva I., Pecheur E., Polyak S. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15: 10: 997-1005.
5. Blaising J., Polyak S.J., Pecheur E.I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107: 84-94.
6. Leneva I.A., Russell R.J., Boriskin Y.S., Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 2009; 81: 2: 132-140.
7. Brooks M.J., Burtseva E.I., Ellery P.J., Marsh G.A., Lew A.M., Slepushkin A.N. et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012; 84: 1: 170-181.
8. Shi L., Xiong H., He J. et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007;152: 1447-1451.
9. Ленёва И.А., Федякина И.Т., Еропкин М.Ю., Гудова Н.В., Романовская А.А., Даниленко Д.М., Виноградова С.М., Лепешкин А.Ю., Шестопалов А.М. Изучение противовирусной активности отечествен ных противогриппозных химиопрепаратов в культуре клеток и на модели животных. Вопр вирусол 2010; 3: 19-27.
10. Leneva I., Roberts N., Govorkova E. et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza virus. Antivir Res 2000; 48: 101-115.
11. McCullers J.A. Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011; 16: 123-135.
12. Tanaka A., Nakamura S., Seki M. et al. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice. Antivir Ther 2014 Feb 12. doi: 10.3851/IMP2744.
13. Hedlund M., Aschenbrenner L. M., Jensen K. et al. Sialidase-based antiinfluenza virus therapy protects against secondary pneumococcal infection. J Infect Dis. 2010; 201: 1007-1015.
14. McCullers J.A. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190: 519-526.
15. Гуськова T.A., Глушков Р.Г. Арбидол-иммуномодулятор, интерферона, антиоксидант. М.: Тимотек, 1999; 93.
16. Шумилов В.И., Шустер A.M., Лобастов и др. Эффективность Арбидола при профилактике и лечении острых респираторных инфекций. Военно-мед журн 2002; 9: 51-53.
17. Учайкин В.Ф., Харламова С.Г., Чешик С.Г. и др. Применение Арбидола и амиксина в качестве этиотропной терапии гриппа и ОРВИ у детей Педиатрия. 2004; 5: 73-77.
18. Малеев В.В. Селькова Е.П., Простяков И.В., Осипова E.A. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в сезоне 2010/11 гг. Инфекц бол 2012; 10: 3: 15-23.
Review
For citations:
Leneva I.A., Falynskova I.N., Leonova E.I., Fedyakina I.T., Makhmudova N.R., Osipova E.A., Lepekha L.N., Mikhailova N.A., Zverev V.V. Umifenovir (Arbidol) Efficacy in Experimental Mixed Viral and Bacterial Pneumonia of Mice. Antibiot Khimioter = Antibiotics and Chemotherapy. 2014;59(9-10):17-24. (In Russ.)
Views:
729
Email this article 